Asterias Biotherapeutics (NYSEMKT: AST)
Shares of Asterias Biotherpaeutics (AST) are trading higher by 6% in early Tuesday trading, continuing to march higher and realizing an 18% gain in its share price since December 14, 2016. A price alert was triggered from our friends at Trade Ideas.
Shares of AST are currently trading at $4.90 (10:55), a 6% rise since the open. During the past two weeks, AST is trading higher by over 18% on no specific company news. Volume is slightly ahead of normal for this time of the day, with buying pressure driving the share price to an intra-day high of $5.00 per share.
In November, shares of AST traded as high as $5.65 per share, on news of its early success in treating SPI. During a recent conference call, the company featured a patient who has responded very well to the AST therapy.
AST And Stem Cells
AST has treated an initial patient in an effort to treat complete spinal cord injury with the use of stem cells. ADT is currently in a dose escalation trial which has shown efficacy in early clinical data. AST has already provided strong safety and tolerability results from lower dose cohorts, leading to dose escalation approval from the DSMB.
In September, AST reported positive efficacy data for its AST-OPC1 trial from five of its AIS-A patients. Those patients were treated with a two million share dose of the AST-OPC1 cells. At the 90 day follow-up, all of the patients have shown at least one motor level improvement and the efficacy target of 2 of 5 patients achieving at least a two motor skill improvement has already been met.
A two motor skill improvement is correlated with a significant increase in functional ability, as well as the ability for patients to care for themselves.
CNA Finance will keep followers appraised of any new price alerts or company specific news.
Disclosure: This article was written by Kenny Soulstring, and it reflects my own opinions and unique articulation. This article is not intended to offer investing advice, guarantee 100% accurate predictions or to be interpreted as providing a personal recommendation. What I can guarantee, though, is accurate research, thoughtful analysis and an enthusiasm about any stock that I cover.
While I seek to uncover emerging companies that I feel have true value and potential, it’s important that investors assign an appropriate time horizon to each of their investments, understanding that emerging companies need time to mature.
I wrote this article myself and it includes my own research and expresses my own opinions. I am not receiving compensation for it (other than from CNA Finance). I have no business relationship with any company whose stock is mentioned in this article.
Additional Disclosure: I am long AST and may purchase additional shares within the next 72 hours.
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!
[Image Courtesy of Wikimedia]